Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen alpha-1(I) chain (COL1A1) (COL1A1)
- Target
- COL1A1
- Molecular classification
- Other (extracellular matrix structural protein; fibrillar collagen, type I)
01
Overview
Collagen alpha-1(I) chain is the α1 polypeptide component of human type I collagen encoded by the COL1A1 gene. Two pro-α1(I) chains and one pro-α2(I) chain assemble intracellularly into type I procollagen; after extracellular processing, they form cross-linked fibrils that provide tensile strength to connective tissues including bone, tendon, skin, cartilage, and sclera. Mutations in COL1A1 cause osteogenesis imperfecta (various types) and contribute to osteoporosis risk, hernias, and disc disease. As a fibrillar extracellular matrix protein, it is primarily a structural constituent and biomarker rather<seg_83>rather than a conventional drug target.
- Other names
- Collagen, type I, alpha 1alpha-1 type I collagenpro-alpha1(I) chainCOL1A1 protein
02
Mechanism of action
Not applicable for direct targeting. Collagen I-related therapeutic strategies generally act indirectly (e.g., modulating collagen synthesis, processing, or cross-linking), but no canonical drug mechanisms target COL1A1 directly.
03
Biological functions
Extracellular matrix structural constituent conferring tensile strengthFormation of type I procollagen and fibrils (two α1(I) chains with one α2(I) chain from COL1A2), cross-linking into mature collagen fibersTissue support and rigidity/elasticity in bone, tendon, skin, cartilage, and sclera
04
Disease associations
Osteogenesis imperfecta (types I–IV) caused by COL1A1 mutationsOsteoporosis risk associated with COL1A1 Sp1 binding-site polymorphismPredisposition to hernias and degenerative disc disease/disc herniation
05
Safety considerations
Targeting collagen I directly could impair connective tissue integrity, bone strength, and wound healing, given its essential structural role; pathogenic loss or abnormal collagen leads to bone fragility and tissue weakness in OI—highlighting therapeutic risk if inhibited
06
Interacting drugs
None established as direct pharmacologic binders/antagonists of COL1A1; collagen I is not a standard drug target. Some experimental contexts modulate collagen I biogenesis or cross-linking indirectly, but no approved direct drugs are listed.
07
Biomarkers
COL1A1 genetic variants (e.g., Sp1 binding-site polymorphism) as risk markers for osteoporosis and vertebral fractureCOL1A1 pathogenic variants as diagnostic markers for osteogenesis imperfecta subtypes
Beyond the preview
Go deeper on Collagen alpha-1(I) chain (COL1A1) (COL1A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Collagen alpha-1(I) chain (COL1A1) (COL1A1).